NotablePrimary completion date: Dec 2026 to Dec 2027
Study completion date: Dec 2027 to Dec 2028
v19
NotablePrimary completion date: May 2021 to Dec 2026v18Show 5 more changesShow less
Trial status: Completed to Active, Not Recruiting
Study completion date: Dec 2021 to Dec 2027
Eligibility criteria shortened, about 36 words
Secondary endpoints: details revised at 1 of 1 entry
Study description revised
Re-verified, no change to tracked fieldsv17
MinorStudy sites revised (8)v16
Show 14 earlier versionsHide 14 earlier versions
MinorTrial status: Active, Not Recruiting to Completed
Enrollment target: estimated 5000 to confirmed 3294
Primary completion date changed from estimate of Dec 2023 to May 2021
Study completion date changed from estimate of Dec 2024 to Dec 2021
v15
2 versionsRe-verified since Apr 23, 2020, no change to tracked fieldsv13-v14
MinorStudy sites: 10 to 8v12
NotableLead sponsor: Vanderbilt University to Vanderbilt University Medical Center
Study sites: 9 to 10
v11
NotablePrimary completion date: Dec 2016 to Dec 2023
Study completion date: Dec 2017 to Dec 2024
Start date: Jan 2007 to Jan 2002
v10
MinorStudy description expanded, about 3 wordsv9
MinorTrial status: Enrolling by Invitation to Active, Not Recruitingv8
MinorPrimary completion date: Dec 2016
Study completion date: Dec 2016 to Dec 2017
Study description expanded, about 4 words
v7
MinorEligibility criteria expanded, about 21 wordsv6
MinorCollaborators: 1 to 2v5
MinorEligibility criteria shortened, about 14 wordsv4
MinorEligibility criteria shortened, about 9 words
Study title shortened, about 1 word
v3
MinorTrial status: Recruiting to Enrolling by Invitation
Site details revised at 9 of 9 sites
v2
Study First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine the effect of modifiable risk factors on knee function, osteoarthritis, and re-rupture of the anterior cruciate ligament (ACL) following ACL reconstruction.
Trial Details
NCT Number
NCT00463099
Lead Sponsor
Vanderbilt University Medical Center Collaborators: National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)